Found: 15
Select item for more details and to access through your institution.
Seguridad cardiovascular de los medicamentos antidiabéticos.
- Published in:
- Medicina Interna de Mexico, 2021, v. 37, n. 2, p. 244, doi. 10.24245/mim.v37i2.5220
- By:
- Publication type:
- Article
Liraglutida en el contexto actual del tratamiento de la diabetes tipo 2.
- Published in:
- Medicina Interna de Mexico, 2011, v. 27, n. 2, p. 141
- By:
- Publication type:
- Article
TYPE 1 DIABETES CARE IN MEXICO: AN ANALYSIS OF THE RENACED-DT1 NATIONAL REGISTRY.
- Published in:
- Clinical & Translational Investigation / Revista de Investigación Clínica, 2021, v. 73, n. 4, p. 222, doi. 10.24875/RIC.20000498
- By:
- Publication type:
- Article
RIESGO CARDIOVASCULAR Y CONCENTRACIÓN DE COLESTEROL LDL EN ADULTOS CON DIABETES TIPO 1: ANÁLISIS DEL RENACED-DT1.
- Published in:
- Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2023, v. 10, p. 26
- By:
- Publication type:
- Article
Algoritmos para el tratamiento farmacológico de la hiperglucemia en diabetes tipo 2.
- Published in:
- Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2020, v. 7, p. 5, doi. 10.24875/RME.M20000005
- By:
- Publication type:
- Article
Glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus: a brief review.
- Published in:
- Revista Mexicana de Endocrinología, Metabolismo y Nutrición, 2016, v. 3, n. 3, p. 137
- By:
- Publication type:
- Article
Liraglutida y glimepirida para el control glucémico de la diabetes tipo 2. Análisis de la cohorte mexicana de LEAD-3.
- Published in:
- Revista Medica del IMSS, 2010, v. 48, n. 5, p. 543
- By:
- Publication type:
- Article
Erratum. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care 2016;39:1972–1980
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Response to comment on Home et al. Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs. Diabetes Care 2014;37:1237-1245.
- Published in:
- 2014
- By:
- Publication type:
- Letter
Predictive and Explanatory Factors of Change in HbA<sub>1c</sub> in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs.
- Published in:
- 2014
- By:
- Publication type:
- Letter to the Editor
Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Predictive and Explanatory Factors of Change in HbA<sub>1c</sub> in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs.
- Published in:
- Diabetes Care, 2014, v. 37, n. 5, p. 1237, doi. 10.2337/dc13-2413
- By:
- Publication type:
- Article
Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension.
- Published in:
- Archivos de Cardiología de México, 2017, v. 87, n. 4, p. 316, doi. 10.1016/j.acmx.2017.01.001
- By:
- Publication type:
- Article
Metabolic dysfunction-associated steatotic liver disease and atherosclerosis.
- Published in:
- Current Diabetes Reports, 2024, v. 24, n. 7, p. 158, doi. 10.1007/s11892-024-01542-6
- By:
- Publication type:
- Article